June 29, 2018 Source: FierceBiotech 137
Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million investment in series B funding led by Novo Holdings. Earlier in the funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
NBE Therapeutics mainly focuses on next-generation antibody-drug conjugates (ADCs) for improved cancer therapies; the startup is gearing up for an enzymatic approach to the conjugation of small molecules and antibodies. As per the company, it provides more control over where the payload is joined to the antibody than is possible with traditional chemical conjugation which contributes to great stability assisting NBE to use highly toxic payloads without running the risk that they will detach near healthy tissue and cause adverse events
Fueled by CHF 20 million from Novo, NBE is now set to test this idea in the clinic. The first candidate to emerge from the enzymatic ADC platform consists of an anthracycline-based toxin attached to a ROR1-targeting antibody.By Ddu
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.